Uncontrolled hypertension or diabetes Uncontrolled hypertension or uncontrolled diabetes within 14 days prior cycle 1, day 1 Uncontrolled hypertension or diabetes Have uncontrolled diabetes or have hypertension requiring more than 3 medications for control of hypertension. Uncontrolled hypertension or diabetes Uncontrolled diabetes or hypertension Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to start of treatment Uncontrolled diabetes or hypertension Uncontrolled hypertension, uncontrolled pulmonary hypertension or uncontrolled diabetes within 14 days prior to enrollment Uncontrolled diabetes, hypertension or other medical conditions that may interfere with assessment of toxicity Uncontrolled hypertension or uncontrolled diabetes Must not have any uncontrolled hypertension or uncontrolled diabetes within 14 days prior to enrollment. Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to randomization Patients who exhibit uncontrolled hypertension (>= 140/90 mmHg) or uncontrolled diabetes within 14 days prior to registration are NOT eligible for participation Uncontrolled diabetes, heart disease, hypertension Uncontrolled hypertension or diabetes. Uncontrolled diabetes or uncontrolled hypertension within 14 days prior to first dose Uncontrolled hypertension or diabetes Uncontrolled hypertension or uncontrolled diabetes despite medication Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to the first day of treatment Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to randomization No uncontrolled hypertension or uncontrolled diabetes (as determined by the treating physician) within 14 days prior to cycle 1 day 1 Uncontrolled hypertension or diabetes Uncontrolled hypertension or diabetes. Uncontrolled hypertension or diabetes Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to signing consent Patients must not have uncontrolled diabetes, uncontrolled infection despite antibiotics or uncontrolled hypertension within 30 days prior to registration Uncontrolled hypertension or diabetes Uncontrolled diabetes, hypertension or other medical conditions at the time of transition to this study that may interfere with assessment of toxicity Uncontrolled hypertension or diabetes Uncontrolled hypertension or diabetes Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to randomization Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to randomization Predisposing factors to retinal vein occlusion including uncontrolled hypertension, uncontrolled diabetes, uncontrolled hyperlipidemia, and coagulopathy. Uncontrolled diabetes, hypertension or other medical conditions that may interfere with assessment of toxicity. Have uncontrolled diabetes or have hypertension requiring more than 3 medications for control of hypertension. Major co-morbidities (e.g., uncontrolled diabetes, hypertension, etc.) History of chronic disease including diabetes, uncontrolled hypertension or thyroid disease Subjects who have diabetes or uncontrolled hypertension are not eligible; NOTE: for the purposes of this study, uncontrolled will be defined as diastolic pressure over 100 mmHg Uncontrolled chronic illness such as hypertension, diabetes, or heart failure Predisposing factors to retinal vein occlusion, including uncontrolled hypertension, uncontrolled diabetes, uncontrolled hyperlipidemia, and coagulopathy No evidence of intercurrent infection Procurement: Patients with severe intercurrent infection Patients with severe intercurrent infection PROCUREMENT: Patients with severe intercurrent infection TREATMENT: Patients with severe intercurrent infection Patients with a severe intercurrent infection Patients with severe intercurrent infection EXCLUSION - INFUSION: Severe active intercurrent infection Severe intercurrent infection Severe intercurrent infection Severe intercurrent infection Severe acute infection Patients with severe intercurrent infection Severe intercurrent infection EXCLUSION - TREATMENT: Severe intercurrent infection Patients with unstable or severe intercurrent medical conditions such as severe heart or lung disease Patients with unstable or severe intercurrent medical conditions such as severe heart or lung disease AT THE TIME OF INFUSION: Severe intercurrent infection TREATMENT: Severe intercurrent infection Severe intercurrent infection Severe intercurrent infection Severe intercurrent infection Severe intercurrent infection AT THE TIME OF INFUSION: Severe intercurrent infection Severe acute infection Uncontrolled or severe intercurrent medical condition Severe intercurrent infection Patients with unstable or severe intercurrent medical conditions such as severe heart or lung disease Severe systemic infection (i.e., sepsis) Severe intercurrent infections Uncontrolled or severe intercurrent medical condition Patients with sepsis or severe infection Patients with sepsis or severe infection Patients with sepsis or severe infection Patients with severe intercurrent infection Patients with sepsis or severe infection Patients with psychosocial conditions that would prevent study compliance COMORBID CONDITIONS No comorbid conditions that would cause life expectancy of less than 5 years A patient cannot be considered eligible for this study unless ALL of the following conditions are met. Patients with any of the following conditions are NOT eligible for this study. Any medical conditions that, in the Investigator's opinion, would impose excessive risk to the patient or would adversely affect his/her participating in this study. Any of the following cardiac conditions: Any medical conditions that, in the Investigator’s opinion, would impose excessive risk to the patient; examples of such conditions include any pre-existing kidney disease (acute or chronic, unless renal insufficiency is felt to be secondary to MM), hypertension, active seizure disorder or pulmonary diseases that would impose excessive risk to the patient Cardiac or pulmonary conditions that preclude aggressive cytoreductive surgery - Patient presenting with cardiac disorders defined by at least one of the following conditions: Women with skin conditions such as psoriasis, fungal infections, keloids etc., or tattoos and/or piercings, which in the opinion of the Investigator, would interfere with absorption of the IP. Has significant, ongoing, co-morbid conditions which would preclude safe delivery of the study drug. Any history of CTCAE grade ?2 non-dysrhythmia cardiac conditions within the last 6 months. Patients with asymptomatic grade 2 non-dysrhythmia cardiac conditions may be considered for inclusion, with the approval of the medical monitor, if stable and unlikely to affect patient safety. Patients with hospitalization within 4 weeks of treatment initiation date for co-morbid conditions or any complication of disease or therapy that is deemed by the principal investigator as unstable or incompletely treated Patients with underlying heart conditions who are deemed ineligible for surgery by cardiology consult; patients with reversible ischemic changes on cardiac stress test History of neurological conditions that would confound assessment of treatment-emergent neuropathy Any medical conditions that, in the Investigator's opinion, would impose excessive risk to the patient or would adversely affect his/her participating in this study. Examples of such conditions are: a significant history of cardiovascular disease (e.g., myocardial infarction, significant conduction system abnormalities, uncontrolled hypertension, ? Grade 3 thromboembolic event in the last 6 months) Subjects must be deemed unfit for RC due to comorbid conditions with a risk of mortality. Has ocular conditions such as: Known risk factors for ocular toxicity Exclusions Related to Autoimmune Conditions and Immunomodulatory Drugs Any medical conditions that, in the investigator’s opinion, would impose excessive risk to the patient or would adversely affect his/her participating in this study, including: Medical conditions, per the investigator’s judgment, that predispose the patient to untoward medical risk in the event of volume loading (e.g. intravenous [IV] fluid bolus infusion), tachycardia, or hypotension during or following treatment with Pexa-Vec History of the following cardiac conditions: History of neurological conditions that would confound assessment of treatment-emergent neuropathy Subjects with any of the following conditions are excluded: Patients with inoperable conditions with resectable disease (T1-2NoMo) Has ocular conditions such as: The patient has cardiac conditions defined per protocol Has a medical or psychosocial conditions that would prevent study compliance Has a history of any of conditions that would contraindicate administration of an OC cardiac conditions, including Any medical conditions that, in the investigator’s opinion, would impose excessive risk to the subject\r\n* Examples of such conditions include:\r\n** Any uncontrolled disease, such as pulmonary disease, infection, seizure disorder\r\n** Any altered mental status or any psychiatric condition that would interfere with the understanding of the informed consent\r\n** Active infection that requires parenteral anti-microbial or anti-parasitic treatment Subject has any underlying conditions, which would contraindicate therapy with study treatment Mild autoimmune conditions (such as localized psoriasis) requiring minimal treatment or systemic autoimmune conditions well controlled by target agents such as an anti-IL-17 that do not affect overall immune system Cardiac or pulmonary conditions that preclude aggressive cytoreductive surgery Patients with known genetic metabolic conditions, or other ongoing serious medical issues, must be approved by the Study Chair prior to registration Patients with any other concurrent uncontrolled illness, including mental illness or substance abuse, which may interfere with the ability of the patient to cooperate and participate in the trial; other examples of such conditions would include COPD or diabetes mellitus that has required 2 or more hospitalizations in the last year; severe peripheral vascular disease; poorly controlled auto-immune conditions; recent serious trauma. uncontrolled comorbid conditions Any of the following cardiac conditions: Any of the following conditions: Other uncontrolled serious chronic disease or conditions that in the investigator's opinion could render compliance or follow-up in the protocol problematic Concurrent conditions as listed in the protocol. Cardiac conditions per protocol Diseases or conditions that obscure toxicity or dangerously alter drug metabolism No diagnosed psychosocial conditions that would hinder study compliance and follow-up No psychosocial conditions that would hinder study compliance and follow-up Untreated psychiatric conditions preventing informed consent Maintenance of castrate conditions History of, or at risk for, cardiac disease, as evidenced by 1 or more of the following conditions: Has ocular conditions such as: Other immunosuppressive medications such as methotrexate, cyclosporine, azathioprine or conditions such as common variable hypogammaglobulinemia Any of the following cardiac conditions: Other uncontrolled serious chronic disease or conditions that in the investigator's opinion could affect compliance or follow-up in the protocol be able to understand the reason for complying with the special conditions of the pregnancy prevention risk management plan and give written acknowledgement of this. Any medical conditions that, in the Investigator's opinion, would impose excessive risk to the patient or would adversely affect his/her participation in this study known glaucoma or other pre-existing ocular conditions that may put the patient at risk for ocular toxicities. Presence or documented history of any of the following autoimmune conditions: Patients with any of the following constitutional conditions are not eligible:\r\n* Fanconi anemia\r\n* Shwachman syndrome\r\n* Any other known bone marrow failure syndrome\r\n* Patients with constitutional trisomy 21 or with constitutional mosaicism of trisomy 21 \r\nNote: enrollment may occur pending results of clinically indicated studies to exclude these conditions Any of the following cardiac conditions: Other uncontrolled serious chronic disease or conditions that in the investigator's opinion could affect compliance or follow-up in the protocol Other uncontrolled serious chronic disease or conditions that in the investigator's opinion could affect compliance or follow-up in the protocol Ophthalmological conditions Medical conditions that, in the investigator’s opinion, would impose excessive risk to the subject COHORT A: Patients with underlying heart conditions who are deemed ineligible for surgery Patients with malabsorption in the small intestine or other conditions that would preclude administration of oral medication Other conditions or circumstances that could interfere with the study Life-expectancy based on comorbid conditions > 2 years Generally healthy other than for CTCL, or with other stable diseases/conditions that are adequately controlled Currently have or have history of certain study-specified heart, liver, kidney, lung, neurological, immune or other medical conditions Patients with underlying heart conditions who are deemed ineligible for surgery by cardiology consult Patients with psychosocial conditions that would prevent study compliance and follow-up, as determined by the principal investigator. Medical/surgical conditions contrary to the kyphoplasty procedure (e.g., presence of active or incompletely treated local infection, severe pulmonary insufficiency), Any other circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol Psychiatric conditions/diseases that impair the ability to give informed consent or to adequately co-operate Diseases or conditions that obscure toxicity or dangerously alter drug metabolism Use of any medical conditions that, in the Investigator's opinion, would impose excessive risk to the patient. Patients with conditions that would prevent absorption of the study drug Patients with underlying heart conditions who are deemed ineligible for surgery by cardiology consult Cardiac conditions Any conditions associated with non-compliance. Patients with comorbid medical conditions that render them unfit for surgery Any other significant co-morbid conditions that would impair study participation or cooperation Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol Known intercurrent infections (including hepatitis C virus and human immunodeficiency virus or other conditions), or clinical evidence of these conditions Currently have or have history of certain study-specified heart, liver, kidney, lung, neurological, immune or other medical conditions Patients with underlying heart conditions who are deemed ineligible for surgery by cardiology consult Active inflammatory or infectious conditions in either eye or history of idiopathic or autoimmune-associated uveitis Conditions that may increase intraocular pressure (e.g. glaucoma, acute globe injury) Skin conditions involving open sores on the scalp that would prevent proper application of the electrodes History of any cardiovascular disease (CVD) or any other medical conditions (e.g. severe osteoarthritis) that will prevent him from walking Medical conditions that would prohibit the safe implementation of a yoga practice (e.g., vertigo, compromised mental status) EXCLUSION - STUDY 1: Have other medical conditions that may affect their balance and gait, or are unable to ambulate without assistance Skin conditions such as open sores that would prevent proper application of the electrodes Conditions that could affect participation in yoga such as spinal disease or unstable joints Any significant comorbid conditions that would interfere with or preclude participation in an exercise intervention, including orthopedic conditions such as advanced osteoarthritis, mobility-limiting amputations or chronic injuries, or mobility-limiting acute orthopedic injuries Chronic inflammatory conditions Skin conditions such as open sores that would prevent proper application of the electrodes Skin conditions such as open sores that would prevent proper application of the electrodes Major medical conditions involving the immune system such as autoimmune and/or inflammatory diseases Significant cardiopulmonary disease, severe arthritis, glaucoma, or any other medical conditions that make yoga practice unsafe as determined by a study investigator Evidence of any of the following conditions per subject self-report or medical chart review: Neurological conditions that affect balance and, or muscle strength Severe cardiovascular, pulmonary or other systemic conditions that prevent participation in the study Participants with the following underlying medical conditions: multiple myeloma, myasthenia gravis, dysproteinemias, severe cardiac disease, aortic stenosis, primary pulmonary hypertension, cardiac arrhythmia, or severe cardiomyopathy. These underlying medical conditions may make the participant more likely to develop a contrast reaction. This is based on the American College of Radiology (ACR) contrast manual version 10.3 and hospital policy. Patients must have no other chronic disease that would preclude randomization into a lifestyle intervention trial; such diseases include recent myocardial infarction or unstable angina (in the previous 6 months), chronic hepatitis, rheumatoid disease, renal or hepatic disease/dysfunction and diabetics receiving insulin; or other clinical condition limiting ability to walk (recent leg fracture, significant osteoarthritis, related orthopedic conditions, degenerative neurological conditions, etc.) Patients with other medical conditions judged by the investigator to be clinically relevant in the setting of this study, which may include active infectious processes, intractable emesis, or chronic diarrheal disease Diabetic neuropathy or other neurological conditions Conditions contraindicated to progesterone treatment. PATIENT: Patients with cardiac shunts or unstable cardiopulmonary conditions Metals or any conditions (e.g. hip prosthesis) that can distort the local magnetic field Patients with cardiac shunts or unstable cardiopulmonary conditions. Conditions which make repeat TRUS biopsies not feasible Preexisting medical conditions or claustrophobic reactions, and any greater than normal potential for cardiac arrest Any medical conditions that, in the Investigator's opinion, would impose excessive risk to the patient or would adversely affect his/her participating in this study Patients with unstable cardiopulmonary conditions Medical conditions such as ischemic heart or lung disease that may be considered an unacceptable risk. Any medical conditions that would impose excessive risk to the patient, or would adversely affect his/her participation in the study Significant history of medical conditions as listed in the protocol. Conditions that could interfere with treatment or protocol-related procedures Serious psychiatric or medical conditions that could interfere with treatment Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as: Presence of any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study Patients must have no serious or uncontrolled medical conditions Medical or psychiatric conditions that preclude informed decision-making or compliance with the protocol treatment or follow-up Have serious preexisting medical conditions. Patients with a significant other medical conditions that would make them unsuitable for transplant Other serious uncontrolled medical conditions that the investigator feels might compromise study participation Have serious preexisting medical conditions Other concurrent severe and/or uncontrolled medical conditions Co-existing medical conditions with life expectancy < 5 years Serious psychiatric or medical conditions that could interfere with treatment Serious psychiatric or medical conditions that could interfere with treatment Participants who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study Serious psychiatric or medical conditions that could interfere with treatment or protocol-related procedures. Other significant medical conditions must be well-controlled and stable in the opinion of the investigator for at least 30 days prior to Randomization Serious psychiatric or medical conditions that could interfere with treatment Patients with concurrent uncontrolled medical conditions that may interfere with their participation in the study or potentially affect the interpretation of the study data Patients with concurrent uncontrolled medical conditions that may interfere with their participation in the study or potentially affect the interpretation of the study data Other concurrent severe and/or uncontrolled medical conditions Patients with concurrent uncontrolled medical conditions that may interfere with their participation in the study or potentially affect the interpretation of the study data Serious psychiatric or medical conditions that could interfere with treatment Patients with other medical conditions or concomitant medications that in the opinion of the principal investigator may interfere with the therapeutic treatment. Patients with co-existing medical conditions with life expectancy < 2 years Patients who have any severe and/or uncontrolled medical conditions Serious psychiatric or medical conditions that could interfere with treatment Clinically relevant serious co-morbid medical conditions. Other serious illness or medical conditions Any severe and/or uncontrolled medical conditions or other conditions that, in the treating physician's opinion, could adversely impact their ability to participate in the study Subjects with certain medical conditions Patients must not have any severe and/or uncontrolled medical condition or other\n conditions that could affect their participation in the study, including, but not\n restricted to: Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study a known history of human immunodeficiency virus (HIV) seropositivity Unstable or severe intercurrent medical or psychiatric conditions as determined by the Investigator Medical Conditions Unstable or serious concurrent medical conditions in the previous 6 months. Evidence of any other medical conditions (such as psychiatric illness, infectious diseases, neurological conditions, physical examination or laboratory findings) that may interfere with the planned treatment, affect patient compliance or place the patient at high risk from treatment related complications Has certain serious illnesses or medical conditions Any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study. Severe or uncontrolled medical conditions Evidence of any other medical conditions (such as psychiatric illness, peptic ulcer, etc.), physical examination or laboratory findings that may interfere with the planned treatment, affect patient compliance or place the patient at high risk from treatment-related complications Have other significant medical conditions well-controlled and stable in the opinion of the investigator for at least 30 days prior to Day 1 Certain serious illnesses or medical conditions Other concurrent serious diseases that may interfere with planned treatment including severe pulmonary conditions/illness Conditions that could interfere with treatment or protocol-related procedures Serious psychiatric or medical conditions that could interfere with treatment Serious psychiatric or medical conditions that could interfere with treatment Serious psychiatric illness (e.g., depression, psychosis) or medical conditions that could interfere with treatment Serious psychiatric or medical conditions that could interfere with treatment Other acute or chronic medical or psychiatric conditions. Patients with a significant other medical conditions that would make them unsuitable for transplant Other serious medical conditions that may be expected to limit life expectancy to less than 2 years (e.g., active liver cirrhosis) or a serious illness in medical opinion of the clinical investigator. Other serious uncontrolled medical conditions that the investigator feels might compromise study participation Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study Excluded medical conditions: Evidence of any other medical conditions (such as psychiatric illness, peptic ulcer, etc.), physical examination or laboratory findings that may interfere with the planned treatment, affect patient compliance or place the patient at high risk from treatment-related complications Other serious uncontrolled medical conditions that the investigator feels might compromise study participation Medical conditions that require hospitalization. Other serious uncontrolled medical conditions that the investigator feels might compromise study participation Patients with unstable or severe intercurrent medical conditions or laboratory abnormalities that would impart, in the judgment of the Medical Monitor, excess risk associated with study participation or study agent administration Patients must not suffer from medical or psychiatric conditions that would interfere with protocol compliance, the ability to provide informed consent, or assessment of response or anticipated toxicities Other concurrent severe and/or uncontrolled medical conditions. Any other serious uncontrolled medical disorders or psychological conditions that may interfere with study conduct Patients with serious psychiatric or medical conditions that could interfere with treatment Any other serious uncontrolled medical disorders or psychological conditions that may interfere with study conduct including but not limited to: clinically significant active infection Other serious medical conditions that may be expected to limit life expectancy to less than 2 years (e.g., active liver cirrhosis) or a serious illness in medical opinion of the clinical investigator. Serious psychiatric or medical conditions that could interfere with treatment Serious cardiac illness or medical conditions Any significant or severe medical conditions or psychiatric or social conditions that would preclude adherence to the protocol or compliance with study treatments Have serious preexisting medical conditions (left to the discretion of the investigator). Exclusionary concurrent medical conditions: Other serious uncontrolled medical conditions that the investigator feels might compromise study participation Conditions that could interfere with treatment and procedures Participants who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study Serious psychiatric or medical conditions that could interfere with treatment Must not have a serious preexisting medical conditions or concomitant disorders. Patients with concurrent uncontrolled medical conditions that may interfere with their participation in the study Other conditions that could interfere with treatment Severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as: Serious psychiatric or medical conditions that could interfere with treatment Participants with severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study Patients must have no serious or uncontrolled medical conditions Uncontrolled or unstable medical conditions Serious psychiatric or medical conditions that could interfere with treatment Patients with any serious active or co-morbid medical conditions, laboratory abnormality, psychiatric illness, active or uncontrolled infections, or serious illnesses or medical conditions that would prevent the patient from participating or to be managed according to the protocol (according to investigator’s decision) Patients who have any severe and/or uncontrolled medical conditions Serious preexisting medical conditions Have serious preexisting medical conditions Any other serious uncontrolled medical disorders or psychological conditions Serious psychiatric or medical conditions that could interfere with treatment No co-existing medical conditions with life expectancy < 5 years Subjects who have used massage as a therapeutic modality (medical or psychological) at any point in their lives for the treatment of medical conditions Uncontrolled concurrent medical conditions that would limit compliance with study requirements There must be no uncontrolled active infections or medical conditions that the investigator feels will compromise the safety of the treatment and/or the assessment of the efficacy of therapy Patients with concurrent uncontrolled medical conditions that may interfere with their participation in the study or potentially affect the interpretation of the study data Subjects who have used massage as a therapeutic modality (medical or psychological) at any point in their lives for the treatment of medical conditions Able to list all current medications and medical conditions Conditions that could interfere with treatment or protocol-related procedures Patients who have any severe and/or uncontrolled medical conditions such as: Uncontrolled or unstable medical conditions Have serious preexisting medical conditions (left to the discretion of the investigator). Other Medical Conditions as noted in the protocol. Patients with other major uncontrolled medical conditions, e.g., recent myocardial infarction, stroke, diabetes, active hepatitis Has any psychiatric or medical disorder that would preclude safe participation in and/or adherence to the protocol Any uncontrolled medical or psychiatric disorder that would preclude participation as outlined Any uncontrolled active medical disorder that would preclude participation as outlined Any uncontrolled active medical disorder that would preclude participation Any uncontrolled medical or psychiatric disorder that would preclude participation Any uncontrolled active medical disorder that would preclude participation as outlined Any uncontrolled active medical disorder that would preclude participation Any uncontrolled active medical disorder that would preclude participation as outlined Any uncontrolled active medical disorder that would preclude participation as outlined Psychiatric disorder or social or geographic situation that would preclude study participation. Psychiatric disorder that would preclude study participation